The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
Authors
Keywords
-
Journal
DRUGS IN R&D
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-08-29
DOI
10.1007/s40268-023-00434-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sphingosine-1-phosphate
- (2022) Patrice Therond et al. CURRENT OPINION IN LIPIDOLOGY
- Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing–remitting multiple sclerosis: findings from randomized controlled trials
- (2022) Siyuan Yang et al. NEUROLOGICAL SCIENCES
- Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK
- (2022) S. Montgomery et al. JOURNAL OF MEDICAL ECONOMICS
- Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models
- (2022) Michael Dietrich et al. Neurology-Neuroimmunology & Neuroinflammation
- Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
- (2022) Gianmarco Abbadessa et al. Journal of Clinical Medicine
- Protective effect of the sphingosine-1 phosphate receptor agonist siponimod on disrupted blood brain barrier function
- (2021) Simona Federica Spampinato et al. BIOCHEMICAL PHARMACOLOGY
- Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis
- (2021) Reshmi Roy et al. CNS DRUGS
- Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland
- (2021) Nadine Schur et al. PHARMACOECONOMICS
- Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses
- (2021) Imtiaz A. Samjoo et al. CURRENT MEDICAL RESEARCH AND OPINION
- Severe lymphopenia switching from Fingolimod to Siponimod
- (2021) Maddalena Sparaco et al. NEUROLOGICAL SCIENCES
- Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis
- (2021) Izanne Roos et al. NEUROLOGY
- Ocular adverse events from pharmacological treatment in patients with multiple sclerosis—A systematic review of the literature
- (2021) Juliana Muñoz-Ortiz et al. Systematic Reviews
- Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets
- (2020) Maria Hjorth et al. PLoS One
- The 2013 clinical course descriptors for multiple sclerosis
- (2020) Fred D. Lublin et al. NEUROLOGY
- Does Siponimod Exert Direct Effects in the Central Nervous System?
- (2020) Markus Kipp Cells
- Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation
- (2020) Alessandra Roggeri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects
- (2020) Jerold Chun et al. DRUGS
- Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
- (2019) Hans Lassmann Frontiers in Immunology
- Siponimod: First Global Approval
- (2019) Zaina T. Al-Salama DRUGS
- Early switch to fingolimod reduces rates of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies
- (2019) Judith Haas et al. Multiple Sclerosis and Related Disorders
- Siponimod in the treatment of multiple sclerosis
- (2019) Andrew D Goodman et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Clinical activity after fingolimod cessation: disease reactivation or rebound?
- (2018) J. Frau et al. EUROPEAN JOURNAL OF NEUROLOGY
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
- (2018) Alan J Thompson et al. LANCET NEUROLOGY
- Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod
- (2018) Tomasz Litwin et al. Neurologia i Neurochirurgia Polska
- The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
- (2018) Andrea Huwiler et al. PHARMACOLOGY & THERAPEUTICS
- The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination
- (2017) Abdelkrim Mannioui et al. Multiple Sclerosis Journal
- Sphingolipids and their metabolism in physiology and disease
- (2017) Yusuf A. Hannun et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases
- (2017) Sinead O'Sullivan et al. NEUROPHARMACOLOGY
- Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis
- (2017) Burhan Z. Chaudhry et al. Neurotherapeutics
- Complex interactions of circadian rhythms, eating behaviors, and the gastrointestinal microbiota and their potential impact on health
- (2017) Jennifer L Kaczmarek et al. NUTRITION REVIEWS
- Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
- (2017) Alberto Gajofatto Drug Design Development and Therapy
- The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination
- (2017) Abdelkrim Mannioui et al. Multiple Sclerosis Journal
- Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
- (2016) Antonietta Gentile et al. Journal of Neuroinflammation
- The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures
- (2016) Catherine O’Sullivan et al. Journal of Neuroinflammation
- Acute relapse after initiation of Siponimod in a patient with secondary progressive MS
- (2016) Rehana Hussain et al. JOURNAL OF NEUROLOGY
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis
- (2016) Ludwig Kappos et al. JAMA Neurology
- Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations
- (2016) Ingo Kleiter et al. Therapeutics and Clinical Risk Management
- The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue
- (2015) Emmanuel E. Egom et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Role of the innate and adaptive immune responses in the course of multiple sclerosis
- (2015) Bernhard Hemmer et al. LANCET NEUROLOGY
- Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis
- (2014) Mark Sanford DRUGS
- Defining the clinical course of multiple sclerosis: The 2013 revisions
- (2014) F. D. Lublin et al. NEUROLOGY
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
- (2013) Krzysztof Selmaj et al. LANCET NEUROLOGY
- Fingolimod Therapy for Multiple Sclerosis
- (2013) Mary Willis et al. SEMINARS IN NEUROLOGY
- Progressive multiple sclerosis: pathology and pathogenesis
- (2012) Hans Lassmann et al. Nature Reviews Neurology
- Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
- (2011) Jeffrey A. Cohen et al. ANNALS OF NEUROLOGY
- Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis
- (2011) Sarah Al-Izki et al. Multiple Sclerosis Journal
- Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions
- (2010) Ruben Van Doorn et al. GLIA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started